Healthcare
Veracyte, Inc. (VCYT)
Data as of July 17, 2026
Environment story
Veracyte discloses no quantified Scope 1, 2, or 3 emissions data in the 10-K. No net-zero target year is stated. No direct decarbonization initiatives, renewable energy commitments, or climate strategy are mentioned. The company operates CLIA-certified clinical reference laboratories (South San Francisco, San Diego, Austin) and manufactures diagnostic test kits. Without disclosed emissions baselines, net-zero commitments, or mitigation strategies, environmental scoring reflects substantial information gaps. The company's business model involves laboratory operations and kit manufacturing but does not appear to generate substantial direct operational carbon intensity relative to competitors in heavy manufacturing or energy sectors.
Criticisms on file
No material criticisms on file for this pillar.
Disclosed initiatives
No disclosed initiatives on file for this pillar.
Social story
Veracyte discloses no CEO-to-median-worker pay ratio, executive or board diversity metrics, or turnover rates in the 10-K. No labor disputes, union activity, or NLRB complaints are mentioned. No supply-chain labor audits or human-rights due diligence are disclosed. The company acquired C2i Genomics in early 2024, with noted risk of integration disruption due to Middle East geopolitical conditions affecting Israeli operations and personnel. Without disclosed diversity percentages, pay equity data, or labor relations information, social scoring reflects material data gaps. The company's business does not involve extractive supply chains (e.g., cobalt/lithium mining) typical of hardware manufacturers.
Criticisms on file
-
Geopolitical risk to C2i operations: Ongoing Middle East conflict may disrupt Israeli operations, facilities, employee access to utilities, and business continuity; integration disruption acknowledged.Source: VCYT 10-K Risk Factors – C2i Integration section
Disclosed initiatives
No disclosed initiatives on file for this pillar.
Governance story
Veracyte discloses no board composition, board independence percentage, or share class structure in the 10-K excerpt provided. No lobbying expenditures, PAC contributions, or political activity are disclosed. No significant antitrust, SEC consent decrees, or regulatory fines are reported. FDA enforcement discretion over Laboratory Developed Tests (LDTs) was vacated in March 2025, creating regulatory uncertainty; the company notes potential future FDA enforcement action against its core LDT products (Decipher Prostate, Afirma, Decipher Bladder) if enforcement discretion is revoked. No active litigation, shareholder proposals, or governance controversies are disclosed. Board independence and voting structure data are absent from provided documents.
Criticisms on file
-
FDA LDT enforcement discretion vacated March 31, 2025: Federal court vacated May 2024 FDA final rule phasing out enforcement discretion; uncertainty remains whether FDA will pursue enforcement against Decipher Prostate, Afirma, and Decipher Bladder LDTs, which represent core revenue.Source: VCYT 10-K Risk Factors – FDA regulation of LDTs section
Disclosed initiatives
No disclosed initiatives on file for this pillar.
These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Veracyte, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Veracyte, Inc. in the app for interactive charts and portfolio building.
Browse Companies · Methodology · Terms of Service · Privacy Policy · Back to Missionomics